- Home
- TSAT vs IMMP Comparison
TSAT vs IMMP Comparison
Compare TSAT & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSAT
- IMMP
- Stock Information
- Founded
- TSAT 1969
- IMMP 1987
- Country
- TSAT Canada
- IMMP Australia
- Employees
- TSAT N/A
- IMMP N/A
- Industry
- TSAT Metal Fabrications
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- TSAT Industrials
- IMMP Health Care
- Exchange
- TSAT Nasdaq
- IMMP Nasdaq
- Market Cap
- TSAT 233.1M
- IMMP 244.5M
- IPO Year
- TSAT 1996
- IMMP N/A
- Fundamental
- Price
- TSAT $26.47
- IMMP $1.71
- Analyst Decision
- TSAT
- IMMP Buy
- Analyst Count
- TSAT 0
- IMMP 1
- Target Price
- TSAT N/A
- IMMP $7.00
- AVG Volume (30 Days)
- TSAT 179.5K
- IMMP 83.4K
- Earning Date
- TSAT 08-13-2025
- IMMP 02-27-2025
- Dividend Yield
- TSAT N/A
- IMMP N/A
- EPS Growth
- TSAT N/A
- IMMP N/A
- EPS
- TSAT N/A
- IMMP N/A
- Revenue
- TSAT $372,642,710.00
- IMMP $3,019,249.00
- Revenue This Year
- TSAT N/A
- IMMP $50.37
- Revenue Next Year
- TSAT N/A
- IMMP N/A
- P/E Ratio
- TSAT N/A
- IMMP N/A
- Revenue Growth
- TSAT N/A
- IMMP 24.11
- 52 Week Low
- TSAT $7.21
- IMMP $1.32
- 52 Week High
- TSAT $27.73
- IMMP $2.72
- Technical
- Relative Strength Index (RSI)
- TSAT 67.61
- IMMP 49.36
- Support Level
- TSAT $23.20
- IMMP $1.60
- Resistance Level
- TSAT $27.73
- IMMP $1.72
- Average True Range (ATR)
- TSAT 1.37
- IMMP 0.06
- MACD
- TSAT -0.06
- IMMP 0.01
- Stochastic Oscillator
- TSAT 83.22
- IMMP 62.14
About TSAT Telesat Corporation and Class B Variable Voting Shares
Telesat Corp is a satellite operator, that provides its customers with mission-critical communications services. It operates in a single operating segment, in which it provides satellite-based services to its broadcast, enterprise, and consulting customers around the world. Geographically, it derives a majority of its revenue from Canada. It derives revenue from Broadcast, Enterprise, Consulting, and others.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.